APGE VS COLL Stock Comparison
Performance
APGE28/100
28/100
APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.
COLL71/100
71/100
COLL returned 15.82% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 70 of 100.
Earnings
APGE100/100
100/100
APGE has missed earnings 1 times in the last 20 quarters.
COLL10/100
10/100
COLL has missed earnings 13 times in the last 20 quarters.
Volatility
APGE44/100
44/100
APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
COLL49/100
49/100
COLL has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
Analyst Price Targets
APGE
"Analyst Price Targets" not found for APGE
COLL86/100
86/100
7 analysts offer 12-month price targets for COLL. Together, they have an average target of 35, the most optimistic target put COLL at 35 within 12-months and the most pessimistic has COLL at 35.
Sentiment
APGE
"Sentiment" not found for APGE
COLL66/100
66/100
COLL had a bullish sentiment score of 65.84% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.00 comments, and 0.00 likes per day.
Technicals
APGE
"Technicals" not found for APGE
COLL89/100
89/100
COLL receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
Profit
APGE
"Profit" not found for APGE
COLL55/100
55/100
Out of the last 20 quarters, COLL has had 11 profitable quarters and has increased their profits year over year on 8 of them.
All score calculations are broken down here to help you make more informed investing decisions
Apogee Therapeutics, Inc. Common Stock Summary
Nasdaq / APGE
Healthcare
Biotechnology
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Collegium Pharmaceutical, Inc. Common Stock Summary
Nasdaq / COLL
Healthcare
Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare APGE to other companies in the same or a similar industry.
